European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 17 · Tue 6 Oct 

Molecules

Lysergide

LSD, DT120

1 asset2 European trial records0 deals

Chemical class
ergoline alkaloid
Mechanism
Not independently verified.

Assets

European trials

Czechia 2

France 2

Germany 2

Poland 2

Our calls

  • Issue 4HITDefinium's Panorama (Phase 3 GAD, DT120 100µg, with 50µg low-dose unblinding-control arm + EU sites) will show a SMALLER placebo-adjusted effect than its sister trial Voyage (same indication/scale, no low-dose arm). Tests whether the Emerge headline is drug or expectancy.

Record history